bp control and stroke pro calcium blockers “melee mayer” con calcium blockers “power-punch...
TRANSCRIPT
BP Control and Stroke
Pro Calcium Blockers“Melee Mayer”
Con Calcium Blockers“Power-Punch Pancioli”
Stephan A. “Melee”
Mayer, MD
Calcium Channel Blockers for Stroke: PRO
Stephan A. Mayer, MDAssociate Professor of Neurology & NeurosurgeryColumbia University Director, Neuro-ICUNew York Presbyterian HospitalNew York, NY
Outcome after Acute Ischemic Stroke by Admission Blood Pressure
90 –
80 –
70 –
60 –
50 –
40 –
30 –
20 –
10 –
0 –n = 18< 120
n = 29121 -140
n = 39141 -160
n = 78161 -180
n = 49181 -200
n = 87> 200
Pos
t neu
rolo
gica
l out
com
e %
Systolic BP on admission (mm Hg)
C
90 –
80 –
70 –
60 –
50 –
40 –
30 –
20 –
10 –
0 –n = 18< 120
n = 29121 -140
n = 39141 -160
n = 78161 -180
n = 49181 -200
n = 87> 200
Ear
ly n
euro
logi
cal d
eter
iora
tion
%
Systolic BP on admission (mm Hg)
A
90 –
80 –
70 –
60 –
50 –
40 –
30 –
20 –
10 –
0 –Pos
t neu
rolo
gica
l out
com
e %
Diastolic BP on admission (mm Hg)
D
n = 38< 70
n = 3971 -80
n = 4881 -90
n = 4391 -100
n = 30101 -110
n = 102> 110
90 –
80 –
70 –
60 –
50 –
40 –
30 –
20 –
10 –
0 –n = 38< 70
n = 3971 -80
n = 4881 -90
n = 4391 -100
n = 30101 -110
n = 102> 110
Ear
ly n
euro
logi
cal d
eter
iora
tion
%
Diastolic BP on admission (mm Hg)
B
Castillo J, et al. Stroke. 2004;35:520–526.
Management of Hypertension in Acute Ischemic Stroke: Patients Not Eligible for
tPA
• SBP <220 mm Hg or DBP <120 mm Hg– No antihypertensive therapy
• SBP >220 mm Hg or DBP >120 mm Hg– Labetalol 20, 40, 60, 80 mg IVP– Nicardipine 5–15 mg/h
Adams HP, et al. Stroke. 2003;34:1056–1083.
SBP, systolic blood pressure; DBP, diastolic blood pressure.
Management of Hypertension in Acute Ischemic Stroke: Patients Eligible for tPA (Pre and Post)
Adams HP, et al. Stroke. 2003;34:1056–1083.
• SBP <180 mm Hg and DBP <105 mm Hg– No antihypertensive therapy
• SBP >180 mm Hg or DBP >105 mm Hg– Labetalol 20, 40, 60, 80 mg IVP– Nicardipine 5–15 mg/h
Treatment of Hypertension in Acute ICH (1999)
Recommendations• Maintain MAP <130 mm Hg and SBP
<180 mm Hg if history of hypertension
• If ICP monitored, keep CPP (MAP – ICP) >70 mm Hg
CPP, cerebral perfusion pressure; MAP, mean arterial pressure; ICP, intracranial pressure. Broderick JP, et al. Stroke. 1999;30:905–915.
High or Low Admission SBP in ICH Patients Correlates with Increased
Mortality
<120 121-140 141-160 161-180 181-200 201-220 >220
n = 7 n = 24 n = 34 n = 50 n = 39 N = 24 n = 13
0
10
20
30
40
50
60
70
80
90
100†NC
*
N = 191.*P < 0.001 vs SBP 141–160 mm Hg on admission.†P < 0.05 vs SBP 141–160 mm Hg on admission.NC, confidence interval not calculated due to <8 cases.
1 month 12 months
Mo
rtal
ity
Rat
e (%
)
SBP (mm Hg)
Adapted from: Vemmos KN, et al. J Intern Med. 2004;255:257-265.
Cerebral Autoregulation Is Central to Treatment of Hypertensive Crises
100 200
normotensive
chronic hypertensive
Increasing risk of hypertensive
encephalopathy
Increasing risk of ischemia
50 150 250
Patients with cerebral ischemia lose their ability to autoregulate
vasoparalysis
Cerebral Blood Flow
Adapted with permission from Varon J, Marik PE. Chest. 2000;118:214–227.
MAP (mm Hg)
Specific Agents
Antihypertensive Agents Used in Hypertensive Crisis
• Clonidine• Diazoxide• Enalaprilat• Esmolol• Fenoldopam• Hydralazine• Labetalol• Nicardipine• Nifedipine• Nitroglycerin• Nitroprusside• Phentolamine• Trimethaphan
Antihypertensive Agents Used in Hypertensive Crisis
• Clonidine• Diazoxide• Enalaprilat• Esmolol• Fenoldopam• Hydralazine• Labetalol• Nicardipine• Nifedipine• Nitroglycerin• Nitroprusside• Phentolamine• Trimethaphan
Antihypertensive “Escalation” for Emergency Treatment of Hypertension
• Nitroprusside– Cerebral vasodilation may
produce or aggravate increased ICP
• Nicardipine• Labetalol or esmolol
– May worsen bronchospasm– Causes bradycardia– May worsen heart failure
• Nitropaste
Increasing Severity of Hypertension
Nitroprusside: NOT the Greatest BP Agent for Patients with Stroke
• Unstable dose-response relationship
• Directly increases ICP via cerebral vasodilation
• Toxicity with longer infusions (>72 hours)
Nicardipine vs Nitroprusside:Postoperative Hypertension Titration
of Study Medications
Halpern NA, et al. Crit Care Med. 1992;20:1637–1643.
Time to Response
(min)
Number of Dose
ChangesAdverse Events
Nicardipine
(n = 71)14.1 ± 1 1.5 ± 0.2 7%
Nitroprusside
(n = 68)30 ± 3.5 5.1 ± 1.4 18%
P = 0.003 P < 0.05
Mean ± SEM.
Nicardipine: Pharmacokinetics of IV Bolus Administration
Adapted from Cheung AT, et al. Anesth Analg. 1999;89:1116.
-50
-40
-30
-20
-10
0
10
0 20 40 60 80 100
Ch
ang
e i
n M
AP
(m
m H
g)
Nicardipine Concentration (ng/mL)120 140
0
50
100
150
0 0.5 1.0 1.5 2.0 2.5 3.0 3.5Time after Drug Administration (h)
Pla
sma
Nic
ard
ipin
e C
on
cen
trat
ion
(n
g/m
L)
Group 1: 0.25 mgGroup 2: 0.5 mgGroup 3: 1.0 mgGroup 4: 2.0 mg
Nicardipine vs Adrenergic BlockersDrug
Nicardipine(Cardene® IV)
Esmolol(Brevibloc®)
Labetalol
Administration Continuous infusion*
Bolus,
continuous
infusion
Bolus,
continuous infusion
Onset + offset Rapid Rapid Slower
Contractility 0 Decreased Decreased
HR Minimal increase Decreased Decreased
SVR Decreased 0 Decreased
Cardiac output Increased Decreased +/-
Myocardial O2 balance
Positive Positive Positive
Contraindications Advanced aortic stenosis
Bradycardia
Heart block >1°
CHF
Bronchospasm
COPD
Bradycardia
Heart block >1°
CHF
Bronchospasm
COPD
Nicardipine
Labetalol
The Evidence Base
Randomized controlled trials comparing nicardipine and labetalol for BP control in ED-treated stroke patients
HA HA HA!
Acute Intracerebral Hemorrhage
Approximately 2 hours after onset of symptoms
“Soft Landing” in a Narrow Target Range
0
20
40
60
80
100
120
140
160
180
200
3:00 4:00 5:00 6:00 7:00 8:00 9:00
Time
mm
Hg
10
Nicardipine Infusion Dose (mg/h)
15 8
SBP MAP DBPTarget SBPTarget MAP Range
“Jagged” BP Profile with Intermittent IVP
0
20
40
60
80
100
120
140
160
180
200
3:00 4:00 5:00 6:00 7:00 8:00 9:00
Time
mm
Hg
Labetalol 40 mg IVP
SBP MAP DBPTarget SBPTarget MAP Range
Calcium Channel Blockers for Acute Stroke?
• Calcium channel blockers directly counteract the neurogenic pressor response
• Consider the IV infusion approach
• This is what we will do in the ICU
• EDs need to function as ICUs
Neurocritical Care Societywww.neurocriticalcare.org
Arthur M. “Power-Punch”
Pancioli, MD
Con: Blood Pressure Management in Stroke Calcium Channel Blockers
Arthur M. Pancioli, MD, FACEP
Associate Professor and Vice Chairman for Research
Department of Emergency Medicine
University of Cincinnati, College of Medicine
Director of Emergency Cerebrovascular Research
Greater Cincinnati/Northern Kentucky Stroke Team
Outline
• The Disease States
• Why Lower Blood Pressure?
• How to Do It?
The Disease States
• Acute ischemic stroke
• ICH
• Subarachnoid hemorrhage
Acute Ischemic Stroke
ICHICH
Early Hemorrhage Growth in Patients With ICH
Growth at 1 hour on CTGrowth at 1 hour on CT >33% Growth>33% Growth 33% Growth33% Growth
Change in NIH Stroke ScaleChange in NIH Stroke Scale 3.7 3.7 ± ± 5.25.2 0.4 ± 2.60.4 ± 2.6
Rankin Scale (4Rankin Scale (4––6 weeks)6 weeks) 4.5 4.5 ± ± 0.90.9 3.8 3.8 ± ± 1.61.6
30-Day mortality30-Day mortality 44%44% 34%34%
Brott T, et al. Stroke. 1997;28:1–5.
Aneurysmal Subarachnoid Hemorrhage
Outcome If You “Rebleed” After Sentinel Subarachnoid Hemorrhage
• Rebleeding significantly increased the odds of death (OR, 2.6; 95% CI, 1.1 to 6.3; P = 0.048)
• Reduced the odds of survival with good outcome (OR, 0.34; 95% CI, 0.13 to 0.92; P = 0.041)
Beck J, et al. Stroke. 2006;37:2733–2737.
The Dance
CPP = MAP – (ICP or CVP)
When is MAP high enough?
When is MAP too high?
My Experience with Calcium Channel Blockers
Should a moratorium be placed on sublingual
nifedipine capsules given for hypertensive emergencies and
pseudoemergencies?
JAMA, Volume 276, Number 16, October 23, 1996
Nimodipine: Subarachnoid Nimodipine: Subarachnoid HemorrhageHemorrhage
• Nimotop® (nimodipine) is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (ie, Hunt and Hess Grades I-V).
DO NOT ADMINISTER NIMOTOP INTRAVENOUSLY OR BY OTHER PARENTERAL ROUTES. DEATHS AND SERIOUS, LIFE-THREATENING ADVERSE EVENTS HAVE OCCURRED WHEN THE CONTENTS OF NIMOTOP CAPSULES HAVE BEEN INJECTED PARENTERALLY.
• (See WARNINGS and DOSAGE AND ADMINISTRATION.)
Titratable Agents for Hypertensive Cerebrovascular Emergencies
What Do I Want?
• Predictability
• Speed
• Ease
Let’s Go Disease by Disease
Acute Ischemic Stroke:
SBP >220 mm Hg / DBP >120 mm Hg
OR - when using tPA:
SBP <185 mm Hg / DBP <110 mm Hg
• IF I MUST – Then I have a lot more experience with labetalol and it reliably does BOTH the things I want
Let’s Go Disease by Disease
ICH:Keep MAP <130 mm Hg but >70 mm Hg
Subarachnoid Hemorrhage:Keep MAP <130 mm Hg but >70 mm HgGeneral rule: keep SBP <160 mm Hg
• WHEN I CAN – I Like labetalol or esmolol; they do everything I want and I can choose how to do it
Pro Calcium Blockers“Melee Mayer”
Con Calcium Blockers“Power-Punch Pancioli”
My Memories of Your Therapy
By The Way
• If we haven’t said it yet:
• I am NOT a hydralazine fan– It has defined unpredictable in my world
By the Way,Nitroprusside
and ICP
Changes in Intracranial
Pressure with Nitroprusside
Therapy
Time for a CONFESSION